Britain and America have forged a major trade agreement that will guarantee zero duties on British drug exports going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to increase spending on drugs through the public health system. This commitment secures that duties on these key products will remain at nothing for a timeframe of three years.
This agreement is in response to previous warnings to dramatically increase tariffs on patented pharmaceutical imports, with figures discussed reaching 100%.
"This agreement with the United Kingdom strengthens the global environment for cutting-edge drugs and introduces much-needed balance to transatlantic medicine commerce," an announcement noted.
Trade Importance
Medicines represent one of the Britain's most significant export categories to the United States, which is by far the largest market for leading British pharmaceutical firms.
Statistics reveal that in the 12 months leading up to last September, the UK exported drugs totaling over eleven billion pounds to the US. This figure accounted for 17.4% of all goods exports in that period.
"This agreement secures work, stimulates capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a minister commented.
Key UK Commitments
The pact involves several key commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to control costs will be limited at fifteen percent. In the past, rebates were more than twenty percent.
Broader Context
The pact comes amid a protracted row between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
This friction were exacerbated by assertions that American customers were paying several times more for the equivalent treatments than patients in the other developed nations.
Recently, several significant drug company projects in the UK have been paused or scrapped, while major expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on medicines, noting that its spending on drugs had decreased as a percentage of its resources over the past decade.
